

ACSAP 2022 Book 3 (*Neurologic Care and Pain Management*)

Release date: November 15, 2022

BCACP test deadline: 11:59 p.m. (Central) on May 15, 2023.

ACPE test deadline: 11:59 p.m. (Central) on November 15, 2025.



Continuing Pharmacy Education Credit: The American College of Clinical Pharmacy

and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education (CPE).

ACSAP Target Audience: The target audience for ACSAP 2022 Book 3 (*Neurologic Care and Pain Management*) is board-certified and advanced level ambulatory care clinical pharmacists who provide care for patients with or at risk of conditions related to neurology, pain, and substance use disorders.

Module 1 (3.50 CPE) Neurologic Care and Pain Management I

UAN: 0217-9999-22-243-H01-P

Chapter: Attention-Deficit/Hyperactivity Disorder

Learning Objectives

1. Evaluate the signs and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adults based on *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* criteria.
2. Distinguish rating scales used for ADHD in children and adults.
3. Evaluate the most updated guideline recommendations for treating ADHD in children and adults.
4. Distinguish the treatment modalities for ADHD including nonpharmacologic and pharmacologic modalities.
5. Evaluate the acute and chronic adverse effects associated with stimulant and nonstimulant medications and strategies to minimize the adverse effects.
6. Synthesize a therapeutic regimen using appropriate agents for management of ADHD symptoms with appropriate goals of therapy.

Chapter: Epilepsy in Adults

Learning Objectives

1. Classify seizures based on presentation and diagnostic considerations.
2. Evaluate an antiseizure medication regimen and develop a patient-specific monitoring plan for a patient with newly diagnosed epilepsy or with drug-resistant epilepsy.
3. Identify nonpharmacological treatment options for patients with drug-resistant epilepsy.
4. Assess treatment considerations of epilepsy in older adults and women.

5. Apply knowledge of comorbidities and patient-specific considerations common in people with epilepsy to the role of pharmacists.

Module 2 (4.50 CPE) Neurologic Care and Pain Management II

UAN: 0217-9999-22-244-H01-P

Chapter: Sleep-Wake Disorders

Learning Objectives

1. Develop a pharmacotherapy and monitoring plan for a patient with insomnia disorder according to recent guidelines and patient-specific characteristics.
2. Design an appropriate therapeutic plan for deprescribing benzodiazepines and non-benzodiazepine receptor agonists in patients using these agents for management of sleep-wake disorders.
3. Devise an appropriate pharmacotherapy and monitoring plan for the management of complications secondary to narcolepsy according to recent guidelines and patient-specific characteristics.
4. Justify appropriate screening, nonpharmacotherapy, pharmacotherapy, medication administration, and monitoring for patients with obstructive sleep apnea or narcolepsy according to recent guidelines and patient-specific characteristics.
5. Design appropriate pharmacotherapy and medication administration for patients with circadian rhythm sleep-wake disorders.
6. Develop a pharmacotherapy and monitoring plan for a patient with restless legs syndrome according to recent guidelines and patient-specific characteristics.

Chapter: Multiple Sclerosis

Learning Objectives

1. Classify the variabilities in patient presentation and the multiple sclerosis (MS) disease course.
2. Analyze MS characteristics to distinguish the spectrum of MS and diagnostic subtypes.
3. Evaluate disease-modifying therapies for MS.
4. Apply knowledge of the MS subtypes and available MS treatments to select appropriate therapy.
5. Assess treatment considerations of MS in pediatric patients and during family planning and pregnancy.

Module 3 (3.50 CPE) Neurologic Care and Pain Management III

UAN: 0217-9999-22-245-H01-P

Chapter: Gabapentinoid Misuse

Learning Objectives

1. Evaluate current clinical evidence regarding the safety and efficacy of off-label use of gabapentinoids.
2. Analyze the physiologic basis for gabapentinoid clinical effects and misuse liability.
3. Evaluate the most common patterns of gabapentinoid misuse.

4. Analyze the current and changing regulatory status of gabapentinoids related to misuse.
5. Design strategies for recognizing and managing gabapentinoid misuse in ambulatory care pharmacy practice.

Chapter: Opioid Overdose Prevention

Learning Objectives

1. Assess the role of outpatient pharmacists in preventing opioid-related harm.
2. Demonstrate the ability to ensure safe and appropriate patient and caregiver use of naloxone.
3. Distinguish key neurobiology factors of opioid use disorder and acute opioid overdose.
4. Apply the screening, brief intervention, and referral to treatment process to a patient case.
5. Devise a business plan for opioid overdose prevention considering the financial, legal, and ethical principles at play.
6. Demonstrate a patient-centered, non-stigmatizing approach to patient care and community education for opioid overdose prevention.

Module 4 (4.50 CPE) Neurologic Care and Pain Management IV

UAN: 0217-9999-22-246-H01-P

Interactive Case: Statewide Tobacco Cessation Protocols

Learning Objectives

1. Assess current policy solutions involving pharmacists to address tobacco use.
2. Discover the process for creating a statewide tobacco cessation protocol, including forming connections with key stakeholders.
3. Develop a strategy for implementing a statewide tobacco cessation protocol in a pharmacy setting.
4. Devise a tobacco cessation treatment plan for a patient using a statewide tobacco cessation protocol.

Interactive Case: Migraine Headache

Learning Objectives

1. Assess the benefits and limitations of novel treatments for patients with migraine headaches.
2. Develop an appropriate treatment plan for an adult or pediatric patient with migraine headache, including acute treatment, prophylactic treatment, and patient education.
3. Justify drug therapy selection for migraine headache considering patient symptoms, comorbid conditions, and medication cost.
4. Design an appropriate treatment plan for a patient with medication overuse headache.

Interactive Case: Bias and Stigmatization in Substance Use Disorders

Learning Objectives

1. Analyze bias and stigmatization toward patients with substance use disorder.
2. Assess the impact of bias and stigmatization on the substance use disorder care continuum.
3. Evaluate mitigation strategies to reduce negative outcomes caused by bias and stigmatization in the care of patients with substance use disorder.